1
|
Konnova A, De Winter FHR, Gupta A, Verbruggen L, Hotterbeekx A, Berkell M, Teuwen LA, Vanhoutte G, Peeters B, Raats S, der Massen IV, De Keersmaecker S, Debie Y, Huizing M, Pannus P, Neven KY, Ariën KK, Martens GA, Bulcke MVD, Roelant E, Desombere I, Anguille S, Berneman Z, Goossens ME, Goossens H, Malhotra-Kumar S, Tacconelli E, Vandamme T, Peeters M, van Dam P, Kumar-Singh S. Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors. Front Immunol 2022; 13:1062136. [PMID: 36618384 PMCID: PMC9813584 DOI: 10.3389/fimmu.2022.1062136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Accepted: 12/05/2022] [Indexed: 12/24/2022] Open
Abstract
Background Patients with cancer, especially hematological cancer, are at increased risk for breakthrough COVID-19 infection. So far, a predictive biomarker that can assess compromised vaccine-induced anti-SARS-CoV-2 immunity in cancer patients has not been proposed. Methods We employed machine learning approaches to identify a biomarker signature based on blood cytokines, chemokines, and immune- and non-immune-related growth factors linked to vaccine immunogenicity in 199 cancer patients receiving the BNT162b2 vaccine. Results C-reactive protein (general marker of inflammation), interleukin (IL)-15 (a pro-inflammatory cytokine), IL-18 (interferon-gamma inducing factor), and placental growth factor (an angiogenic cytokine) correctly classified patients with a diminished vaccine response assessed at day 49 with >80% accuracy. Amongst these, CRP showed the highest predictive value for poor response to vaccine administration. Importantly, this unique signature of vaccine response was present at different studied timepoints both before and after vaccination and was not majorly affected by different anti-cancer treatments. Conclusion We propose a blood-based signature of cytokines and growth factors that can be employed in identifying cancer patients at persistent high risk of COVID-19 despite vaccination with BNT162b2. Our data also suggest that such a signature may reflect the inherent immunological constitution of some cancer patients who are refractive to immunotherapy.
Collapse
Affiliation(s)
- Angelina Konnova
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium,Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
| | - Fien H. R. De Winter
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
| | - Akshita Gupta
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium,Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
| | - Lise Verbruggen
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
| | - An Hotterbeekx
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium
| | - Matilda Berkell
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium,Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
| | - Laure-Anne Teuwen
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Greetje Vanhoutte
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Bart Peeters
- Department of Laboratory Medicine, Antwerp University Hospital, Edegem, Belgium
| | - Silke Raats
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
| | - Isolde Van der Massen
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
| | - Sven De Keersmaecker
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium
| | - Yana Debie
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Manon Huizing
- Biobank, Antwerp University Hospital, Edegem, Belgium
| | - Pieter Pannus
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium
| | - Kristof Y. Neven
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium,Centre for Environmental Sciences, Hasselt University, Hasselt, Belgium,Federal Public Service (FPS) Health, Food Chain Safety and Environment, Brussels, Belgium
| | - Kevin K. Ariën
- Virology Unit, Institute of Tropical Medicine Antwerp, Antwerp, Belgium,Department of Biomedical Sciences, University of Antwerp, Edegem, Belgium
| | - Geert A. Martens
- Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium
| | - Marc Van Den Bulcke
- Scientific Directorate Epidemiology and Public Health, Sciensano, Brussels, Belgium
| | - Ella Roelant
- Clinical Trial Center (CTC), Clinical Research Centre (CRC) Antwerp, Antwerp University Hospital, University of Antwerp, Edegem, Belgium,StatUa, Center for Statistics, University of Antwerp, Antwerp, Belgium
| | - Isabelle Desombere
- Service Immune response, Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium
| | - Sébastien Anguille
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Zwi Berneman
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Maria E. Goossens
- Scientific Directorate Infectious Diseases in Humans, Sciensano, Brussels, Belgium
| | - Herman Goossens
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
| | - Surbhi Malhotra-Kumar
- Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium
| | - Evelina Tacconelli
- Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - Timon Vandamme
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Marc Peeters
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Peter van Dam
- Multidisciplinary Oncological Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium
| | - Samir Kumar-Singh
- Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium,Laboratory of Medical Microbiology, Vaccine and Infectious disease Institute, University of Antwerp, Wilrijk, Belgium,*Correspondence: Samir Kumar-Singh,
| |
Collapse
|
2
|
Gerits E, Van der Massen I, Vandamme K, De Cremer K, De Brucker K, Thevissen K, Cammue BPA, Beullens S, Fauvart M, Verstraeten N, Michiels J. In vitro activity of the antiasthmatic drug zafirlukast against the oral pathogens Porphyromonas gingivalis and Streptococcus mutans. FEMS Microbiol Lett 2017; 364:fnx005. [PMID: 28087617 DOI: 10.1093/femsle/fnx005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2016] [Accepted: 01/10/2017] [Indexed: 11/13/2022] Open
Abstract
Oral infections are among the most common diseases worldwide. Many protocols for the prevention and treatment of oral infections have been described, yet no golden standard has been developed so far. The antiseptic chlorhexidine and antibiotics are often used in these treatment procedures. However, long-term use of chlorhexidine can lead to side effects and extensive use of antibiotics can promote the development of antibiotic-resistant bacteria, which in turn can compromise the effectiveness of the treatment. Consequently, it remains important to search for new antibacterial agents for the treatment of oral infections. In this study, we report on the antibacterial activity of the antiasthma drug zafirlukast against oral pathogens Porphyromonas gingivalis and Streptococcus mutans. Furthermore, its activity against oral biofilms grown on titanium surfaces was confirmed. In addition, we demonstrated that zafirlukast displays no cytotoxicity against human osteoblasts. Combined, this study paves the way for further research to determine the potential of zafirlukast to be used as a new antibiotic against oral pathogens.
Collapse
Affiliation(s)
- Evelien Gerits
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Isolde Van der Massen
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Katleen Vandamme
- UZ Leuven, Restorative Dentistry- KU Leuven, BIOMAT, Department of Oral Health Sciences, 3000 Leuven, Belgium
| | - Kaat De Cremer
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium.,VIB, Department of Plant Systems Biology, 9052 Ghent, Belgium
| | - Katrijn De Brucker
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Karin Thevissen
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Bruno P A Cammue
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium.,VIB, Department of Plant Systems Biology, 9052 Ghent, Belgium
| | - Serge Beullens
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Maarten Fauvart
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium.,IMEC, Smart Systems and Emerging Technologies Unit, Department of Life Science Technologies, 3001 Leuven, Belgium.,Smart Systems and Emerging Technologies Unit, Department of Life Science Technologies, imec, Leuven, Belgium
| | - Natalie Verstraeten
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| | - Jan Michiels
- KU Leuven, Centre of Microbial and Plant Genetics, Department of Microbial and Molecular Systems, 3001 Leuven, Belgium
| |
Collapse
|